RMTI
Rockwell Medical, Inc. NASDAQ Listed Jan 27, 1998$0.78
Mkt Cap $30.8M
52w Low $0.74
3.2% of range
52w High $2.10
50d MA $0.92
200d MA $1.06
P/E (TTM)
-5.9x
EV/EBITDA
9985.8x
P/B
0.9x
Debt/Equity
0.3x
ROE
-14.4%
P/FCF
-25.0x
RSI (14)
—
ATR (14)
—
Beta
1.71
50d MA
$0.92
200d MA
$1.06
Avg Volume
260.6K
Rockwell Medical, Inc., together with its subsidiaries, operates as a biopharmaceutical company that targets end-stage renal disease and chronic kidney disease with therapies and products for the treatment of iron deficiency and hemodialysis in the United States and internationally. The company offers Triferic Dialysate and Triferic AVNU, an iron therapy that replaces iron and maintains hemoglobin in dialysis patients without increasing iron stores. It also manufactures, sells, delivers, and distributes hemodialysis concentrates, such as CitraPure citric acid concentrate, Dri-Sate dry acid concentrate, RenalPure liquid acid concentrate, dry acid concentrate mixer, and RenalPure and SteriLyte powder bicarbonate concentrate; and ancillary products, including blood tubing, fistula needles, dialyzers, drugs, specialized component kits, dressings, cleaning agents, filtration salts, and other supplies used by hemodialysis providers. The company's dialysis concentrate products are used to maintain human life by removing toxins and replacing critical nutrients in the dialysis patient's bloodstream. It is also developing other therapeutic product candidates for the treatment of hospitalized patients with acute heart failure; and home infusion therapy that allows patients to receive intravenous medications at home. Its target customers include medium and small sized dialysis chains and independent dialysis centers. Rockwell Medical, Inc. was incorporated in 1996 and is headquartered in Wixom, Michigan.
30142 South Wixom road · Wixom, MI 48393 · US
| Date | Time | Est | Rptd | Surp | Base | Gap% | D1% | D2% | D3% | D4% | D5% | Guide ▲★ |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| May 7, 2026 | BMO | — | — | — | 0.81 | -1.5% | -3.6% | +6.8% | — | — | — | — |
| Mar 26, 2026 | AMC | 0.04 | -0.01 | -125.0% | 0.94 | -1.3% | -7.6% | -2.3% | +5.1% | +4.5% | +2.5% | — |
| Nov 12, 2025 | AMC | -0.04 | -0.05 | -25.0% | 0.96 | +2.6% | -4.5% | +0.7% | -5.8% | +1.1% | -1.8% | — |
| Aug 14, 2025 | AMC | -0.05 | -0.05 | +0.0% | 1.05 | +1.0% | -2.9% | +2.9% | +0.0% | +0.0% | +10.5% | — |
| May 12, 2025 | AMC | -0.03 | -0.04 | -33.3% | 1.04 | +1.9% | +2.9% | -5.6% | -3.0% | +3.1% | +3.0% | — |
| Mar 20, 2025 | AMC | 0.02 | -0.02 | -200.0% | 1.40 | -0.7% | -3.6% | -6.7% | -4.8% | +3.3% | -3.2% | — |
| Nov 12, 2024 | AMC | 0.01 | 0.05 | +400.0% | 2.83 | +6.0% | -7.1% | -5.3% | -5.2% | -0.4% | +6.0% | — |
| Aug 8, 2024 | AMC | 0.00 | 0.01 | +126.4% | 2.14 | +2.8% | +1.4% | +9.7% | +0.8% | -1.7% | +8.5% | — |
| May 14, 2024 | AMC | -0.05 | -0.02 | +60.0% | 1.70 | -1.8% | +0.6% | +1.8% | +1.7% | +1.7% | +0.0% | — |
| Mar 21, 2024 | AMC | -0.08 | 0.02 | +125.0% | 1.52 | -4.6% | +12.5% | -5.3% | +1.9% | -0.6% | +1.2% | — |
| Nov 14, 2023 | AMC | -0.12 | -0.07 | +41.7% | 1.96 | +3.1% | +12.8% | -6.8% | +0.5% | -5.8% | -2.6% | — |
| Aug 14, 2023 | AMC | -0.12 | -0.18 | -50.0% | 2.85 | -1.1% | -3.2% | -18.1% | -2.2% | +0.0% | +5.9% | — |
| May 15, 2023 | AMC | -0.18 | -0.10 | +44.4% | 2.41 | +2.9% | -2.9% | -0.9% | +1.7% | +0.0% | +8.9% | — |
| Date | Firm | Action | Grade | Target | Base | Open | Gap% | D1% | D2% | D3% | D4% | D5% |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Mar 30 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $0.87 | $0.86 | -0.9% | -2.3% | +5.1% | +4.5% | +2.5% | +0.8% |
| Jan 26 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $1.15 | $1.15 | +0.0% | -5.2% | +5.5% | -1.7% | -3.5% | -1.8% |
| Nov 13 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $0.96 | $0.98 | +2.6% | -4.5% | +0.7% | -5.8% | +1.1% | -1.8% |
| Mar 24 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $1.35 | $1.35 | +0.0% | -6.7% | -4.8% | +3.3% | -3.2% | -5.0% |
| Dec 23 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $2.08 | $2.08 | +0.0% | +1.4% | +1.9% | +0.5% | -0.9% | -4.2% |
| Nov 25 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $2.25 | $2.30 | +2.2% | +2.7% | -2.6% | -1.3% | +3.2% | -2.2% |
| Aug 12 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $2.17 | $2.23 | +2.8% | +9.7% | +0.8% | -1.7% | +8.5% | +0.8% |
| May 16 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $1.71 | $1.73 | +1.2% | +1.8% | +1.7% | +1.7% | +0.0% | +0.6% |
| Mar 25 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $1.71 | $1.68 | -1.8% | -5.3% | +1.9% | -0.6% | +1.2% | +2.4% |
| Nov 15 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $1.96 | $2.02 | +3.1% | +12.8% | -6.8% | +0.5% | -5.8% | -2.6% |
| Oct 4 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $2.06 | $2.05 | -0.5% | +0.5% | +3.4% | +7.0% | -5.7% | +13.0% |
| Sep 28 | HC Wainwright& Co. | Maintains | Buy → Buy | — | $1.85 | $1.85 | +0.0% | +8.1% | +4.0% | -2.4% | +1.5% | +0.5% |
| Sep 28 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $1.85 | $1.85 | +0.0% | +8.1% | +4.0% | -2.4% | +1.5% | +0.5% |
| Aug 15 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $2.85 | $2.82 | -1.1% | -3.2% | -18.1% | -2.2% | +0.0% | +5.9% |
| Jul 17 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $3.19 | $3.49 | +9.4% | +31.3% | -4.1% | +9.0% | -7.3% | -0.7% |
| May 30 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $2.39 | $2.47 | +3.3% | +13.0% | +23.0% | +11.7% | +13.7% | +8.1% |
| May 30 | HC Wainwright& Co. | Maintains | Buy → Buy | — | $2.39 | $2.47 | +3.3% | +13.0% | +23.0% | +11.7% | +13.7% | +8.1% |
| May 2 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $2.94 | $2.98 | +1.4% | -1.7% | +3.1% | -3.0% | -0.7% | +0.0% |
| Apr 4 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $1.80 | $1.80 | +0.0% | +3.9% | -2.7% | +0.0% | +8.8% | +3.0% |
| Feb 13 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $2.15 | $2.27 | +5.6% | +10.2% | +5.5% | +4.8% | -2.7% | -1.6% |
| Feb 8 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $1.90 | $1.86 | -2.1% | +2.1% | +0.5% | +10.3% | +10.2% | +5.5% |
| Aug 30 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $1.42 | $1.57 | +10.6% | +12.7% | +13.1% | +2.8% | -9.1% | -4.7% |
| Jan 18 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $5.17 | $4.73 | -8.5% | +0.0% | +8.5% | -7.8% | -17.0% | -2.6% |
| Sep 7 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $7.04 | $7.15 | +1.6% | +3.1% | -3.0% | -3.1% | +4.8% | -4.6% |
| Feb 8 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $15.07 | $15.84 | +5.1% | +8.0% | +30.4% | -6.2% | -6.1% | +2.9% |
| Apr 7 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $22.99 | $23.32 | +1.4% | -3.8% | +5.5% | +5.2% | +9.9% | +2.4% |
| Nov 12 | Piper Jaffray | Maintains | Overweight → Overweight | — | $21.01 | $21.34 | +1.6% | +2.6% | +2.6% | +4.5% | -0.5% | -1.9% |
| Jun 25 | Cantor Fitzgerald | Maintains | Overweight → Overweight | — | $32.56 | $33.44 | +2.7% | +4.7% | -3.5% | +0.3% | +0.3% | -0.7% |
| Jun 24 | Piper Jaffray | Maintains | Overweight → Overweight | — | $32.89 | $34.10 | +3.7% | -1.0% | +4.7% | -3.5% | +0.3% | +0.3% |
| Oct 19 | IFS Securities | Downgrade | Strong Buy → Outperform | — | $47.19 | $46.64 | -1.2% | -1.2% | +1.4% | +0.7% | -4.4% | +4.1% |
| Aug 14 | IFS Securities | Downgrade | Strong Buy → Buy | — | $68.64 | $69.96 | +1.9% | +5.0% | -2.1% | +0.3% | -3.6% | +1.5% |
| Nov 8 | Bank of America | Downgrade | Neutral → Underperform | — | $62.26 | $44.00 | -29.3% | -20.3% | +8.9% | +4.1% | +7.0% | +4.2% |
| Aug 19 | BTIG Research | Maintains | Buy → Buy | — | $81.07 | $82.17 | +1.4% | -2.0% | +0.0% | +0.4% | -1.2% | -2.5% |
| Mar 1 | Craig-Hallum | Downgrade | Buy → Hold | — | $105.60 | $67.10 | -36.5% | -34.3% | -1.3% | -2.1% | +1.5% | +4.8% |
| Mar 1 | Stifel Nicolaus | Downgrade | Buy → Hold | — | $105.60 | $67.10 | -36.5% | -34.3% | -1.3% | -2.1% | +1.5% | +4.8% |
| Aug 13 | Morgan Stanley | Maintains | Underweight → Underweight | — | $151.14 | $134.53 | -11.0% | -16.0% | +9.6% | -0.1% | -4.1% | -3.5% |
| Jan 7 | Oppenheimer | Maintains | Outperform → Outperform | — | $104.61 | $111.65 | +6.7% | +8.7% | +5.0% | +0.1% | +8.6% | -0.1% |
| Nov 7 | Chardan Capital | Maintains | Buy → Buy | — | $102.63 | $127.82 | +24.5% | +13.1% | +3.3% | +2.3% | +0.8% | -2.0% |
| Aug 14 | FBR Capital | Maintains | Underperform → Underperform | — | $122.65 | $115.39 | -5.9% | -7.9% | -0.3% | +1.5% | -0.8% | -2.0% |
| Dec 19 | Chardan Capital | Maintains | Buy → Buy | — | $115.72 | $120.01 | +3.7% | +6.0% | +2.5% | -2.0% | -0.7% | +0.6% |
| Dec 17 | Brean Capital | Maintains | Sell → Sell | — | $148.17 | $127.27 | -14.1% | -19.8% | -2.6% | +6.0% | +2.5% | -2.0% |
| Sep 13 | Craig-Hallum | Maintains | Buy → Buy | — | $90.53 | $98.01 | +8.3% | +22.8% | -1.1% | -2.3% | -0.2% | -3.7% |
| May 9 | Stifel Nicolaus | Maintains | Buy → Buy | — | $43.56 | $45.65 | +4.8% | -4.8% | +3.4% | -4.1% | -4.0% | -6.7% |
| Nov 27 | Dawson James | Maintains | Market Outperform → Outperform | — | $79.75 | $79.86 | +0.1% | -1.8% | -0.6% | +1.0% | +1.8% | +0.0% |
| Nov 9 | Stifel Nicolaus | Maintains | Buy → Buy | — | $73.04 | $72.05 | -1.4% | -3.8% | -1.6% | +1.6% | -5.9% | -7.0% |
| Apr 11 | Summer Street | Maintains | Buy → Buy | — | $97.35 | $99.11 | +1.8% | +7.9% | -2.2% | -2.2% | +1.1% | +1.5% |
| Mar 12 | Stifel Nicolaus | Maintains | Buy → Buy | — | $98.67 | $103.07 | +4.5% | +8.6% | +0.8% | -6.3% | +6.0% | -2.9% |
No insider trades available.
8-K · 2.02
!! High
Rockwell Medical, Inc. -- 8-K 2.02: Earnings Results
Rockwell Medical reported Q1 2026 financial results, providing investors with updated insights into the company's operational performance and financial condition for the quarter.
May 7
8-K
Rockwell Medical, Inc. -- 8-K Filing
May 7
8-K
Unknown — 8-K Filing
RMTI experienced a material triggering event requiring immediate disclosure, making this 8-K critical for understanding recent developments that could significantly impact the stock's valuation and investor decision-making.
Mar 26
8-K
Unknown — 8-K Filing
Rimini Street (RMTI) achieved sustained profitability with $69.3M revenue in 2025, demonstrating business model viability and potentially supporting stock valuation multiples expansion if growth accelerates.
Mar 26
Data updated apr 26, 2026 11:11pm
· Source: massive.com